Epizyme Inc (NASDAQ:EPZM) Rating Reconfirmed
Today, 28 September, Epizyme Inc (NASDAQ:EPZM) stock Outperform was reconfirmed by RBC Capital Markets in a research report.
NASDAQ:EPZM is now trading -30.07% lower at $12.51 as of 14:52 New York time. Epizyme Inc’s stock is down -14.85% in the last 200 days. It has underperformed the S&P500 Index, which has dropped -6.24% in the same time.
Out of 6 brokers covering Epizyme Inc, 6 rate it a Buy, 1 indicate a Hold while 0 suggest a Sell. The highest target is $42 and the lowest is $22 according to Thomson/First Call. The 12-month mean target is $35.5, which means upside potential of 183.77% over the current price.
Institutional Ownership
Ecor1 Capital Llc had the largest stake with ownership of 1.69 million shares as of q2 2015 for 13.49% of the US long stock exposure. Foresite Capital Management Ii Llc is another very bullish active investment manager who is possessing 897,863 shares of Epizyme Inc or 7.56% of their US long stock exposure. Moreover, Mpm Asset Management Llc have 7.15% of their US long stock exposure invested in the company for 1.78M shares. The Maryland-based fund Nea Management Company Llc revealed it had purchased a stake worth about 6.45% of the active investment manager’s stock portfolio in Epizyme Inc. The New York-based fund Ghost Tree Capital Llc is also positive about the stock, possessing 5.15M shares or 2.07% of their US long stock exposure.
Insider Activity
Over the last six months, Epizyme Inc NASDAQ:EPZM has seen 2 insider buying transactions, and 5 insider sales. The net result was for 7 transactions, worth $3.02M.
Epizyme Inc (NASDAQ:EPZM) Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. The Company’s lead product candidate, EPZ-6438 is an inhibitor that targets the EZH2 HMT.
Epizyme Inc (NASDAQ:EPZM) traded down -30.07% on 28 September, hitting $12.51. A total of 1.25 million shares of the company’s stock traded hands. This is up from average of 440,548 shares. Epizyme Inc has a 52 week low of $12.00 and a 52 week high of $30.26. The company has a market cap of $745.35 million and a P/E ratio of 0.
